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Abstract
Factor X deficiency is a rare autosomal disease with an estimated prevalence 1: 1,000,000. It is characterized by
a reduction in factor X, an essential component of the prothrombinase complex responsible for converting
prothrombin to thrombin. The aim of the study was to identify the molecular defects in the factor X gene in
Palestinian factor X deficient patients. Nine unrelated Palestinian patients were identified by thrombin time [PT],
activated partial thromboplastin time [APTT] and plasma factor X levels. All exons including exon/ intron border and
promoter regions were PCR amplified, purified, sequenced and compared to the normal factor X gene. A novel
splicing junction mutation IVS1+1G˃T was identified in two patients resulting in a major distortion of the protein
structure and function. A second novel missense mutation Asp413Asn G>T that apparently distorts the protein
structure and affects its catalytic activity was identified in the family of one patient. Six patients proved to be
homozygous of the previously identified c358 delG deletion mutation leading to a severely truncated protein that
seems specific to our population. A putatively mild heterozygous mutation Ser105thr G>C was detected in two
patients who suffer from the severe c358 delG deletion mutation.
Keywords: Blood coagulation; Factor X gene variants; Inherited
coagulation disorder; Nucleotide deletion; Gla protein distortion and
activity
Introduction
Factor X is a vitamin K dependent serine protease synthesized in
the liver [1]. After activation by factor IXa [intrinsic pathway] or VIIa
[extrinsic pathway], factor X becomes a major component of the
prothrombinase complex which converts prothrombin into thrombin
[2]. Deficiency in factor X is rare in the world affecting approximately
one in million people [3]. The complete absence of factor X was shown
to be fatal since FX-/- knockout mice failed to survive [3]. It is
inherited as an autosomal recessive disorder resulting in low or
absence of serum protein concentration and severe bleeding disorder
[4]. Factor X deficiency is expressed in two major types where type 1 is
characterized by a significant decrease in the level and function of the
protein while type II results primarily from dysfunction of the protein.
The factor X gene is located on chromosome 13 and consist of 8 exons
[1,5]. Over 100 mutations have been reported thus far in the gene
where missense mutations represent the majority of cases in addition
to deletion/insertion, splice site and non-sense mutations that were
also detected in patients from various populations. These include
fifteen mutations identified in 13 unrelated Iranian families [6], four in
two Chinese families [7,8] and several other mutations were reported
in102 subjects from Europe and Latin America [3]. Furthermore,
additional mutations in the factor X gene were detected in patients
from the USA [9], Saudi Arabia [10], Hungary [11], Germany [12],
Japan [13], France [14], Australia [15] and China [16,17].
Interestingly, a patient with severe factor X deficiency was found to
suffer from deletion of exon 8 in the factor X gene in addition to
deletion of exons 1 and 2 in protein Z gene located downstream from
the factor X gene [18]. Six additional novel missense mutations were
recently identified in six patients [19] and one additional nonsense
novel mutation was identified in 15 factor X deficient patients [20].
Two additional missense mutations were identified in the factor X that
result in moderate FX deficiency due to either decreased secretion [21]
or reduced activity in the intrinsic pathway of the clotting cascade
[22].
Materials and Methods
Seven male and two female patients from nine unrelated families
were identified with severe factor X deficiency and history of bruising,
painful swelling of joints and high PT and partial thromboplastin time
PTT values. Genomic DNA was purified from patients and/or their
parents from whole EDTA venous blood samples using
MasterPureTM Genomic DNA Purification Kit (Epicenter
Technologies, USA). All exons, exon–intron borders and the promoter
regions were PCR amplified as described before [6]. Amplified DNA
fragments were purified using the Wizard® SVGel and PCR Clean-Up
System (Promega) and subjected to direct sequencing using an
automated sequencer (ABI PRISMTM Model 310 Version 3.7). DNA
sequences were read by Finch TV and compared to the factor X gene
sequence stored in the UCSC Genome browser. BLAST search at
NCBI and alignment was applied in order to identify homologies
between the DNA sequences of the purified PCR products with Homo
Sapiens factor X gene stored in the Gene Bank (http://
www.ncbi.nlm.nih.gov/BLAST). The effect of the identified mutations
on the protein sequence of factor X was predicted by the amino acid
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translator program [EX PASY] bioinformatics resource portal
translation tool.
Results
Clinical description of patients
All patients, except patient B, suffered from prolonged PT and
APTT indicating a defect in the common coagulation pathway that
was verified by undetectable levels of plasma factor X. These patients
have a history of easy bruising on their limbs due to minor trauma and
epistaxis, bleeding from umbilical stump, joint swelling and pain. Most
patients result from consanguinity marriages. Patients treatment
include fresh frozen plasma once or twice a month due the lack of
factor X concentrate in the local hospitals. Patient B was a newborn
male patient who was diagnosed with severe factor X deficiency 4
months after birth following a severe brain bleeding condition and
died shortly before genomic DNA could be obtained for genetic
analysis. Alternatively, blood samples were obtained from his parents
to identify the defect in the factor X gene which resulted in their child
clinical condition.
Genetic analysis
All 8 exons and exon/intron borders of the factor X gene were
amplified and subjected to direct sequencing followed by comparison
to the wild type factor X gene sequence. The results from two patients
(20 and 22) revealed the presence of a novel homozygous donor splice-
site mutation in exon 1/intron 1 border (IVS1+1G>T) as shown in
Figure 1A and 1B. All other exons and exon/intron sequences in
addition to the promoter region showed no variation from the normal
gene sequence. A second novel homozygous missense mutation Asp
413Asn G>A was predicted in the gene of the diseased patient (B),
who suffered from major brain bleeding due to severe factor X
deficiency, from the DNA sequence of his parents as shown in Figure
1G and 1H. This mutation lies in the catalytic domain of the factor X
protein responsible for its activity. Six of the nine patients examined in
our study (patients 1,9,14,27,32,X) were found to be homozygous for
the c302delG mutation previously described by Livnat et al. [23] in
three Palestinian factor X deficient patients as shown in Figure 1E and
1F. This mutation results in an early stop codon leading to a severely
truncated protein and seems predominant in the Palestinian
population. Furthermore, an apparently mild missense mutation
Ser105Thr G>C was detected in exon 6 in patients 14 and 27 as shown
in Figure 1C and 1D. Both patients suffer from the c302delG deletion
mutation and are heterozygous for this mutation and therefore has no
relevance to their clinical symptoms. Table 1 summarizes the list of the
identified mutations in the present study including their nature,
location, nucleotide change and effect. In addition to the identified
mutations, several polymorphisms were detected in the promoter and
exons 3,7 and 8 of the factor X gene in seven of examined patients as
described in Table 2. The polymorphism in exon 8 in patients 9 and 14
(G>A corresponding to T293T) represents a new polymorphism in the
gene while the polymorphisms in the promoter region and exons 3
and 7 were reported before. The sequence of the indicated exons and
intron/exon borders from thirty normal individuals with no signs of
bleeding disorder did not reveal any of the identified mutations
detected in the patients. This provides further confirmation that the
identified mutations in the factor X gene form these patients are
responsible for the expressed clinical abnormalities and do not
represent normal variation in the gene.
Sample Mutated exons Mutation Type Nucleotide change Codon/aa change
1 4:Homozygous Frame shift (deletion ) c308 delG Stop codon
9 4:Homozygous Frame shift (deletion ) c308 delG Stop codon
14
4:Homozygous
6:Heterozygous
Frame shift (deletion )
missense
c308 delG
G→C
Stop codon
Ser→Thr
20 1:Homozygous Base substitution G→T 5' donor splicing site
22 1:Homozygous Base substitution G→T 5' donor splicing site
27
6:Heterozygous
4:Homozygous
Missense
Frame shift (deletion )
G→C
c 308 delG
Ser→Thr
Stop codon
32 4:Homozygous Frame shift (deletion ) c 308 delG Stop codon
X 4:Homozygous Frame shift (deletion ) c 308 delG Stop codon
B 8:Homozygous Base substitution G to A (p.D413N) Asp to Asn
Table 1: Mutations identified in the Factor X gene.
Samples Exons Nucleotide change SNPs Reference Number(dbSNP build 137)
1 3 T→C (at position 24) rs2251102
9 8 G→A (at position 55) T293T -Silence Variant(Synonmous Variant)
14 3 T→C (at position 24) rs2251102
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8 G→A (at position 55) T293T -Silence Variant(Synonmous Variant)
20 Promoter
3
7
T→C (at position -139)
C→T (at position 139)
C→T (at position 139)
rs563964
rs2251102
rs5960
22 _ _
27 _ _
32 7 A→G (at position 170) rs2031184
X 3
7
7
T→C (at position 24)
G→A (at position 55)
A→G (at position 192)
rs2251102
rs5960
rs2031184
Table 2: Identified SNPs in the Factor X Gene.
Figure 1: DNA sequences profile of the indicated exons in the factor
X gene illustrating the specific identified nucleotide mutations.
Discussion
Factor X plays a central role in the blood coagulation cascade due to
its involvement in the intrinsic and extrinsic pathways of this vital
process. In the present study, we investigated putative mutations in the
factor X gene in nine unrelated Palestinian patients who suffer from
bleeding disorder due to severe reduction in plasma factor X levels. Six
patients were found to suffer from a deletion mutation that was
previously identified in three unrelated Palestinian patients [24] that
seems predominant in the Palestinian population since it was not
detected in patients from other ethnic groups. A novel mutation which
disturbs the 5' donor splice site in intron 1(IVS1+1G>T) was detected.
Evidently, the consensus sequence at the 5' splicing donor site is (C/
A)AGgt(ag)agt (exonic nucleotides are represented in capital while
intronic nucleotides are represented by lowercase), however, in case of
the factor X gene, the sequences of all splice sites are predominantly
GT-AT which is most dominant in the mammalian genome [25,26].
Mutations in the 5' donor splice site are predominant over mutations
in the 3'acceptor site mostly affecting the G nucleotide at the +1
location [26]. Consequently, mutations in the conserved G nucleotide
is expected to cause exon loss, inclusion of the intron sequence in the
translation sequence or identification of an alternative splice site [24]
which will significantly affect the normal expression and function of
the protein. A related mutation (IVS1+1G>A) was previously
identified in the factor X gene leading to the absence of any detected
transcript which was confirmed by in vitro ectopic transcript analysis
[11]. A similar effect is projected here form the G>A mutation
reported here in the same location in the gene. Another related
mutation (IVS1+3A>T) was previously identified in the factor X gene
resulting in a significant decrease in the plasma protein level [6]. The
donor splice-site sequence mutation primarily results in inclusion of
intron 1 in the coding sequence leading to the identification of an early
stop codon leading to the production of a severely truncated protein or
unstable mRNA that is unable to code for a biologically active factor X
protein. This is confirmed by the absence of detectable plasma factor X
in the plasma of our study patients. Evidently, similar mutations were
reported in the donor exon border splicing sequences of several genes
which result in significant disturbances in the expression and function
of the coded proteins. They include a G>A mutation in intron 7 of the
human Rh50 glycoprotein gene [27], a G>A mutation in intron 2 in
the CYP21 gene [28], a G>C mutation in intron 1 of the peripherin/rds
gene [29], a cryptic donor splice site in intron 19 of the thyroglobulin
gene [30], a C>T mutation and A>G mutation in intron 26 of the Von
Willebrand factor gene [31] and a G>A mutation in intron 25 of the
angiotensin 1-converting enzyme gene [32]. Moreover, another
comparable mutation in the factor X gene (IVS5+1G>A) was reported
in a patient who suffer from compound heterozygous mutations along
with a deletion mutation (Asp409del) and characterized by the
absence of detectable transcript that was further confirmed by ectopic
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transcript analysis [17]. The authors projected a likely mechanism of
the observed clinical expression where the mutation potentially
resulted in the production of an unstable transcript that was quickly
destroyed by the NMD pathway [33]. The absence of detectable factor
X in the plasma of our patients with the G>T mutation at this location
results primarily from a similar defective mechanism leading to the
absence of stable and translatable transcript. Eventually, this mutation
may provide the reason for the utilization of an alternative splicing site
that significantly disrupts the splicing efficiency and producing
unstable transcript leading to the observed phenotype. The majority of
mutations affecting this nucleotide at this location lead to the loss of
an exon as reported in the ATM gene which results in exon 8 skipping
that was associated with frame shift causing premature termination of
the translated message and the expression of ataxia telangectsis [34]. A
similar mutation was also reported in exon 10 of the factor V gene
which resulted in frame shift and premature translation termination
[35].
The novel missense mutation detected in exon 8 which results in
the replacement of acidic amino acid with a neutral polar residue
(Asp413Asn) lies in the critical catalytic domain of the factor X
protein. The nature of this shift in the amino acids type causes a
significant change in the molecular structure of the 185-189 loop
similar to the Asp409 deletion mutation that was reported previously
[17]. This mutation will result in impairment of the catalytic activity of
the FX protein due to the expected negative effect it has on Na+
binding to the indicated loop. Similarly, the Arg347His mutation,
causes a mutation in the same catalytic domain of the F X protein (8),
that results in a dramatic decrease in FX protein activity.
Conclusion
Two mutations were identified in the factor X gene. A novel
homozygous splicing mutation in the 5' donor site (IVS1+1G˃T that
results in a significantly distorted protein and a homozygous missense
novel mutation in exon 8 (Asp413Asn G>T). A heterozygous mild
mutation was also identified in exon 6 of the gene Ser105thr (G>C). In
addition, a previously identified deletion mutation I exon 4 c358 delG
which results in an early stop codon was detected in our investigation
that appears specific to our population.
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